Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial

被引:0
|
作者
Frantz, R. P. [1 ]
McLaughlin, V. V. [2 ]
Sahay, S. [3 ]
Subias, P. Escribano [4 ]
Zolty, R. L. [5 ]
Benza, R. L. [6 ]
Channick, R. N. [7 ]
Chin, K. M. [8 ]
Hemnes, A. R. [9 ]
Howard, L. S. [10 ]
Sitbon, O. [11 ]
Vachiery, J. [12 ]
Zamanian, R. T. [13 ]
Cravets, M. [14 ]
Roscigno, R. F. [15 ]
Mottola, D. [15 ]
Elman, E. [16 ]
Parsley, E. [15 ]
Aranda, R. [17 ]
Zisman, L. S. [15 ]
Ghofrani, H. [18 ]
机构
[1] Mayo Clin, Cardiovasc Med, Rochester, MN USA
[2] Univ Michigan, Cardiovasc Dis, Internal Med, Ann Arbor, MI USA
[3] Houston Methodist Hosp Weill Cornell Med, Div Pulm Crit Care & Sleep Med, Houston, TX USA
[4] Univ Complutense, Univ Hosp Octubre 12, Cardiol, Madrid, Spain
[5] Univ Nebraska Med Ctr, Internal Med, Omaha, NE USA
[6] Ohio State Univ, Wexner Med Ctr, Div Cardiovasc Dis, Columbus, OH USA
[7] UCLA Med Ctr, Pulmonol, Crit Care Med, Los Angeles, CA USA
[8] UT Southwestern Med Ctr, Internal Med, Dallas, TX USA
[9] Vanderbilt Univ, Dept Med, Nashville, TN USA
[10] Imperial Coll Healthcare NHS Trust, Cardiol, London, England
[11] Univ Paris Saclay, Hop Bicetre, Serv Pneumol, Le Kremlin Bicetre, France
[12] HUB Hop Erasme, Cardiol, Brussels, Belgium
[13] Stanford Univ, Sch Med, Pulm & Crit Care Med, Stanford, CA USA
[14] Gossamer Bio Inc, Biometr, San Diego, CA USA
[15] Gossamer Bio Inc, Clin Dev, San Diego, CA USA
[16] Gossamer Bio Inc, Clin Operat, San Diego, CA USA
[17] Gossamer Bio Inc, Clin Execut, San Diego, CA USA
[18] Justus Liebig Univ Giessen, Dept Internal Med, Giessen, Germany
关键词
D O I
暂无
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
A6726
引用
收藏
页数:2
相关论文
共 50 条
  • [21] Measuring the Heart in Pulmonary Arterial Hypertension (PAH): Implications for Trial Study Size
    Bradlow, William M.
    Hughes, Marina L.
    Keenan, Niall G.
    Bucciarelli-Ducci, Chiara
    Assomull, Ravi
    Gibbs, J. Simon R.
    Mohiaddin, Raad H.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2010, 31 (01) : 117 - 124
  • [22] Targeted Therapy of pulmonary arterial Hypertension (PAH)
    Klose, H.
    Opitz, C.
    Bremer, H.
    Ewert, R.
    Bonderman, D.
    Rosenkranz, S.
    Seeger, W.
    Schmeisser, A.
    Harbaum, L.
    Buerke, M.
    Ghofrani, H. Ardeschir
    Borst, M. M.
    Leuchte, H. H.
    Lange, T. J.
    Behr, J.
    Ulrich, S.
    Lang, I.
    Olschewski, H.
    Gall, H.
    Kabitz, H. -J.
    Kleber, F. -X.
    Held, M.
    Hoeper, M. M.
    Gruenig, E.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 : S142 - S150
  • [23] A Literature Review of Pulmonary Arterial Hypertension (PAH)
    Panchal, Ashima
    Panchal, Jigar
    Jain, Sonika
    Dwivedi, Jaya
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2022, 18 (02) : 104 - 114
  • [24] Endothelial dysfunction in pulmonary arterial hypertension (PAH)
    Thambiayya, Kalidasan
    FASEB JOURNAL, 2015, 29
  • [25] Riociguat For The Treatment Of Pulmonary Arterial Hypertension (pah): A Phase Iii Long-Term Extension Study (patent-2)
    Rubin, L. J.
    Galie, N.
    Grimminger, F.
    Grunig, E.
    Humbert, M. J. C.
    Jing, Z. -C.
    Keogh, A. M.
    Langleben, D.
    Fritsch, A.
    Kilama, M. Ochan
    Neuser, D.
    Ghofrani, H. -A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [26] Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH): Results from INSPIRE Study
    Hill, N. S.
    Feldman, J. P.
    Sahay, S.
    Levine, D. J.
    Patel, S.
    Galloway, A.
    Bull, T. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [27] Effect of macitentan on left ventricular (LV) function in pulmonary arterial hypertension (PAH): results from REPAIR
    Rosenkranz, S.
    Channick, R.
    Cottreel, E.
    Galie, N.
    Kiely, D. G.
    Marcus, J. T.
    Swift, A. J.
    Tawakol, A.
    Torbicki, A.
    Noordegraaf, A. Vonk
    Wetherill, G.
    Peacock, A.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2296 - 2296
  • [28] Riociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): 1-Year Results from the PATENT-2 Long-term Extension Study
    Rubin, Lewis
    Galie, Nazzareno
    Grimminger, Friedrich
    Gruenig, Ekkehard
    Humbert, Marc
    Jing, Zhi-Cheng
    Keogh, Anne
    Langleben, David
    Fritsch, Arno
    Menezes, Flavia
    Neuser, Dieter
    Ghofrani, Hossein
    CHEST, 2013, 144 (04)
  • [29] Psychometric Validation of the Pulmonary Arterial Hypertension- Symptoms and Impact (PAH-SYMPACT) Questionnaire Results of the SYMPHONY Trial
    Chin, Kelly M.
    Gomberg-Maitland, Mardi
    Channick, Richard N.
    Cuttica, Michael J.
    Fischer, Aryeh
    Frantz, Robert P.
    Hunsche, Elke
    Kleinman, Leah
    McConnell, John W.
    McLaughlin, Vallerie V.
    Miller, Chad E.
    Zamanian, Roham T.
    Zastrow, Michael S.
    Badesch, David B.
    CHEST, 2018, 154 (04) : 848 - 861
  • [30] Pulmonary Involvement in Systemic Sclerosis and Pulmonary Arterial Hypertension (PAH)
    Graefenstein, K.
    AKTUELLE RHEUMATOLOGIE, 2011, 36 (01) : 47 - 53